**Proteins** 

## **Product** Data Sheet

## VU6028418

Cat. No.: HY-141711 CAS No.: 2649803-05-2 Molecular Formula:  $C_{23}H_{27}F_{3}N_{4}O$ Molecular Weight: 432.48 Target: mAChR

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C 3 years

> 4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 5.56 mg/mL (12.86 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3122 mL	11.5612 mL	23.1225 mL
	5 mM	0.4624 mL	2.3122 mL	4.6245 mL
	10 mM	0.2312 mL	1.1561 mL	2.3122 mL

Please refer to the solubility information to select the appropriate solvent.

<b>D</b> I	$\sim$ 1	001	C A		TIV	171
				A44		

Description VU6028418 is a potent, highly selective and orally bioavailable  $M_4$  mAChR antagonist with an IC<sub>50</sub> of 4.1 nM against  $hM_4^{[1]}$ .

mAChR4 IC<sub>50</sub> & Target

In Vivo VU6028418 is orally bioavailable<sup>[1]</sup>.

In Vivo PK Parameters for VU6028418<sup>[1]</sup>

parameter	rat (SD) <sup>a</sup>	mouse (CD-1) <sup>a</sup>	dog (beagle) <sup>a</sup>
dose (mg/kg) iv/po	1/10	1/3	1/3
CL <sub>p</sub> (mL/min/kg)	6.1	17	43

V <sub>ss</sub> (L/kg)	6.7	10.6	8.5
elimination t <sub>1/2</sub> (h)	13	NC	15
C <sub>max</sub> (ng/mL) po	17 000	181	70
T <sub>max</sub> (h) po	1.5	6.67	17
AUC <sub>0-inf</sub> (ng/mL•h) po	30 000	NC	1100
F (%) po	≥100	≥100	86
total brain/total plasma (K <sub>p</sub> )	6.4	ND	ND
unbound brain/unbound plasma (K <sub>p,uu</sub> )	0.61	ND	ND
CSF/plasma unbound (K <sub>p,u</sub> )	0.24	ND	ND

<sup>&</sup>lt;sup>a</sup> Values represent means from two to three animals. ND = not determined. NC = not calculated; there was insufficient data to define the elimination phase (i.e.,  $C_{max}$  was one of the last three time points).

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$ 

Animal Model:	SD rat, CD-1 mouse and beagle $dog^{[1]}$	
Dosage:	1, 3 and 10 mg/kg	
Administration:	Intravenous injection or oral administration (Pharmacokinetic Analysis)	
Result:	Showed good pharmacokinetic results.	

## **REFERENCES**

[1]. Spock M, et al. Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist. ACS Med Chem Lett. 2021 Aug 2;12(8):1342-1349.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA